Uni-China Group Launches "Hong Kong Farmland" Brand Program

by | PRNewswire Asia

Empowering Local Agriculture and Fisheries with Expertise and TechnologyHeralding a New Era of Sustainable Development HONG KONG, Jan. 20, 2026 /PRNewswire/ — Uni-China Group (hereafter "the Group") officially announced the launch of its flagship...

Sakai Clinic 62 Founder & Medical Director Mari Sakai Holds Dialogue with Peter Nobel, Chairman of the Nobel Sustainability Trust, Declaring Global Leadership as a Pioneer of Medical Sustainability

by | PRNewswire Asia

TOKYO, Jan. 20, 2026 /PRNewswire/ — Sakai Clinic 62 (Location: Shibuya-ku, Tokyo; Founder & Medical Director: Mari Sakai) announces that Dr. Mari Sakai held a dialogue with Mr. Peter Nobel, Chairman of the Nobel Sustainability Trust (NST), to discuss the...

GS1 Hong Kong Applauds HKMA's Project Cargox Recommendation Report, Supporting Hong Kong's Digital Trade Future with Reliable Data Foundation

by | PRNewswire Asia

HONG KONG, Jan. 19, 2026 /PRNewswire/ — GS1 Hong Kong ("GS1 HK") is pleased to share the Hong Kong Monetary Authority’s ("HKMA") release of the Project CargoX Recommendation Report, for which GS1 HK served as a member of the...

Ageing, smoking, oral bacteria and genetic mutations linked to higher stomach cancer risk

by | PRNewswire Asia

Duke-NUS and NUHS scientists uncover a complex web of genetic, age-related and microbial factors that increase the risk of stomach cancer. Age-related blood cell mutations may trigger early changes in the stomach lining, offering new insights into how cancer risk...

Ageing, smoking, oral bacteria and genetic mutations linked to higher stomach cancer risk

by | PRNewswire Asia

Duke-NUS and NUHS scientists uncover a complex web of genetic, age-related and microbial factors that increase the risk of stomach cancer. Age-related blood cell mutations may trigger early changes in the stomach lining, offering new insights into how cancer risk...

Akeso Announces NMPA Acceptance of Second NDA for Gumokimab (IL-17A Inhibitor) in Active Ankylosing Spondylitis

by | PRNewswire Asia

HONG KONG, Jan. 19, 2026 /PRNewswire/ — Akeso, Inc. (9926.HK) announced that its supplemental New Drug Application (sNDA) for gumokimab (AK111), a novel humanized anti-IL-17A monoclonal antibody for the treatment of active ankylosing spondylitis (AS),...